4.7 Article

Reversible Metal-Dependent Destabilization and Stabilization of a Stem-Chelate-Loop Probe Binding to an Unmodified DNA Target

期刊

BIOCONJUGATE CHEMISTRY
卷 23, 期 10, 页码 2020-2024

出版社

AMER CHEMICAL SOC
DOI: 10.1021/bc3003293

关键词

-

资金

  1. National Cancer Institute [R44CA094612, R44CA094612-S2]

向作者/读者索取更多资源

Herein, we report the discovery of a novel DNA probe with a stem-chelate-loop structure, wherein the stability of the probe target duplex can be modulated lower or higher using a narrow concentration range of dilute transition metal ions (0.1-10 mu M). Oligonucleotide probes containing two terpyridine (TPY) ligands separated by 15 bases of single-stranded DNA, with or without a flanking 5 base self-complementary DNA stem, were tested in thermal transition studies with linear target DNA and varying amounts of ZnCl2. Without the stem, addition of Zn2+ resulted only in reversible destabilization of the probe target duplex, consistent with assembly (up to 1 equiv Zn2+) and disassembly (excess Zn2+) of the intramolecular Zn2+-(TPY)(2) chelate. Surprisingly, probes including both the intramolecular chelate and the stem gave a probe-target duplex that was reversibly destabilized and stabilized upon addition of Zn2+ by +/- 5-7 degrees C, a phenomenon consistent with assembly and then disassembly of the entire stem-Zn2+-(TPY)(2) motif, including the DNA stem. Stem-chelate-loop probes containing dipicolylamine (DPA) ligands exhibited no metal-dependent stabilization or destabilization. The stem-Zn2+-(TPY)(2) motif is readily introduced with automated synthesis, and may have broad utility in applications where it is desirable to have both upward and downward, reversible metal-dependent control over probe-target stability involving an unmodified DNA target.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Chemistry, Medicinal

Boronic acid-containing CXCR1/2 antagonists: Optimization of metabolic stability, in vivo evaluation, and a proposed receptor binding model

Dean Y. Maeda, Angela M. Peck, Aaron D. Schuler, Mark T. Quinn, Liliya N. Kirpotina, Winston N. Wicomb, Richard L. Auten, Rambabu Gundla, John A. Zebala

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)

Article Chemistry, Medicinal

Boronic acid-containing aminopyridine- and aminopyrimidinecarboxamide CXCR1/2 antagonists: Optimization of aqueous solubility and oral bioavailability

Aaron D. Schuler, Courtney A. Engles, Dean Y. Maeda, Mark T. Quinn, Liliya N. Kirpotina, Winston N. Wicomb, S. Nicholas Mason, Richard L. Auten, John A. Zebala

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)

Article Multidisciplinary Sciences

Effective combinatorial immunotherapy for castration-resistant prostate cancer

Xin Lu, James W. Horner, Erin Paul, Xiaoying Shang, Patricia Troncoso, Pingna Deng, Shan Jiang, Qing Chang, Denise J. Spring, Padmanee Sharma, John A. Zebala, Dean Y. Maeda, Y. Alan Wang, Ronald A. DePinho

NATURE (2017)

Article Chemistry, Medicinal

Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-yisulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2

Dean Y. Maeda, Angela M. Peck, Aaron D. Schuler, Mark T. Quinn, Liliya N. Kirpotina, Winston N. Wicomb, Guo-Huang Fan, John A. Zebala

JOURNAL OF MEDICINAL CHEMISTRY (2014)

Article Multidisciplinary Sciences

LD-Aminopterin in the Canine Homologue of Human Atopic Dermatitis: A Randomized, Controlled Trial Reveals Dosing Factors Affecting Optimal Therapy

John A. Zebala, Alan Mundell, Linda Messinger, Craig E. Griffin, Aaron D. Schuler, Stuart J. Kahn

PLOS ONE (2014)

Article Oncology

KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer

Wenting Liao, Michael J. Overman, Adam T. Boutin, Xiaoying Shang, Di Zhao, Prasenjit Dey, Jiexi Li, Guocan Wang, Zhengdao Lan, Jun Li, Ming Tang, Shan Jiang, Xingdi Ma, Peiwen Chen, Riham Katkhuda, Krittiya Korphaisarn, Deepavali Chakravarti, Andrew Chang, Denise J. Spring, Qing Chang, Jianhua Zhang, Dipen M. Maru, Dean Y. Maeda, John A. Zebala, Scott Kopetz, Y. Alan Wang, Ronald A. DePinho

CANCER CELL (2019)

Article Clinical Neurology

Desmetramadol Has the Safety and Analgesic Profile of Tramadol Without Its Metabolic Liabilities: Consecutive Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trials

John A. Zebala, Shawn L. Searle, Lynn R. Webster, Matt S. Johnson, Aaron D. Schuler, Dean Y. Maeda, Stuart J. Kahn

JOURNAL OF PAIN (2019)

Article Pharmacology & Pharmacy

Desmetramadol Is Identified as a G-Protein Biased μ Opioid Receptor Agonist

John A. Zebala, Aaron D. Schuler, Stuart J. Kahn, Dean Y. Maeda

FRONTIERS IN PHARMACOLOGY (2020)

Article Oncology

Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination Immunotherapy

Lucas A. Horn, Kristen Fousek, Duane H. Hamilton, James W. Hodge, John A. Zebala, Dean Y. Maeda, Jeffrey Schlom, Claudia Palena

Summary: Innovative strategies involving the addition of cancer vaccines to immune checkpoint blockade therapies can enhance antitumor efficacy by increasing the numbers of tumor-infiltrating T cells. These strategies have shown promising results in preclinical studies and may have potential in improving outcomes for patients resistant to current immunotherapies.

CANCERS (2021)

Article Multidisciplinary Sciences

Single-cell evaluation reveals shifts in the tumor-immune niches that shape and maintain aggressive lesions in the breast

Vidya C. Sinha, Amanda L. Rinkenbaugh, Mingchu Xu, Xinhui Zhou, Xiaomei Zhang, Sabrina Jeter-Jones, Jiansu Shao, Yuan Qi, John A. Zebala, Dean Y. Maeda, Florencia McAllister, Helen Piwnica-Worms

Summary: The aggressive and indolent breast tumor cells are functionally indistinguishable once isolated from their local niche, suggesting the involvement of non-tumor collaborators in determining aggressiveness. Aggressive lesions are characterized by fewer total but more suppressed-like T cells, elevated tumor-promoting neutrophils, and IL-17 signaling, disruption of which can increase tumor latency and reduce the number of aggressive lesions.

NATURE COMMUNICATIONS (2021)

Article Oncology

Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC

Kwan Ho Tang, Shuai Li, Alireza Khodadadi-Jamayran, Jayu Jen, Han Han, Kayla Guidry, Ting Chen, Yuan Hao, Carmine Fedele, John A. Zebala, Dean Y. Maeda, James G. Christensen, Peter Olson, Argus Athanas, Cynthia A. Loomis, Aristotelis Tsirigos, Kwok-Kin Wong, Benjamin G. Neel

Summary: Our study suggests that inhibiting the SHP2/RAS/ERK pathway leads to upregulation of CXCR2 ligands and recruitment of S100A8 hi gMDSCs, suppressing T cells in non-small cell lung cancer. Combining SHP2/CXCR2 inhibitors can block gMDSC immigration, enhance Th1 polarization, induce highly cytotoxic CD8 + KLRG1 + effector T cells, and improve survival.

CANCER DISCOVERY (2022)

Article Oncology

Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer

Pat Gulhati, Aislyn Schalck, Shan Jiang, Xiaoying Shang, Chang-Jiun Wu, Pingping Hou, Sharia Hernandez Ruiz, Luisa Solis Soto, Edwin Parra, Haoqiang Ying, Jincheng Han, Prasenjit Dey, Jun Li, Pingna Deng, Emi Sei, Dean Y. Maeda, John A. Zebala, Denise J. Spring, Michael Kim, Huamin Wang, Anirban Maitra, Dirk Moore, Karen Clise-Dwyer, Y. Alan Wang, Nicholas E. Navin, Ronald A. DePinho

Summary: Pancreatic ductal adenocarcinoma (PDAC) is resistant to PD1 and CTLA4 immune checkpoint therapies. This study characterized the mechanisms of ICT resistance and identified effective therapeutic options. The combination of agonist 41BB and antagonist LAG3 ICT increased survival and antitumor immunity. Triple therapy with T cell-activating ICTs and a CXCR1/2 inhibitor resulted in durable complete responses. This provides a testable hypothesis for clinical testing in human PDAC.

NATURE CANCER (2023)

Article Medicine, Research & Experimental

Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC

Julia Kargl, Xiaodong Zhu, Huajia Zhang, Grace H. Y. Yang, Travis J. Friesen, Melissa Shipley, Dean Y. Maeda, John A. Zebala, Jill McKay-Fleisch, Gavin Meredith, Afshin Mashadi-Hossein, Christina Baik, Robert H. Pierce, Mary W. Redman, Jeffrey C. Thompson, Steven M. Albelda, Hamid Bolouri, A. McGarry Houghton

JCI INSIGHT (2019)

Article Medicine, Research & Experimental

Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy

Lillian Sun, Paul E. Clavijo, Yvette Robbins, Priya Patel, Jay Friedman, Sarah Greene, Rita Das, Chris Silvin, Carter Van Waes, Lucas A. Horn, Jeffrey Schlom, Claudia Palena, Dean Maeda, John Zebala, Clint T. Allen

JCI INSIGHT (2019)

Article Pharmacology & Pharmacy

Intestinal Transport of Aminopterin Enantiomers in Dogs and Humans with Psoriasis Is Stereoselective: Evidence for a Mechanism Involving the Proton-Coupled Folate Transporter

Alan Menter, Breck Thrash, Christina Cherian, Larry H. Matherly, Lei Wang, Aleem Gangjee, Joel R. Morgan, Dean Y. Maeda, Aaron D. Schuler, Stuart J. Kahn, John A. Zebala

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)

暂无数据